Markets

The Zacks Analyst Blog Highlights: Cymabay Therapeutics, Attunity, Lumentum Holdings, Datawatch and Arconic

A generic image of a pair of glasses on top of a calculator
Credit: Shutterstock photo

For Immediate Release

Chicago, IL - February 22, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cymabay Therapeutics, Inc. (NASDAQ: CBAY - Free Report ), Attunity Ltd. (NASDAQ: ATTU - Free Report ), Lumentum Holdings Inc. (NASDAQ: LITE - Free Report ), Datawatch Corp. (NASDAQ: DWCH - Free Report ) and Arconic Inc. (NYSE: ARNC - Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

Top 5 Performers from Trump's First Month in Office

After a brief lull, markets have again hit fresh highs. Investors reaffirmed their faith in the promises of the new administration, and the "Trump Rally" looks set to continue over the current week. Meanwhile, Trump celebrated his first month in office by indicating that these gains were largely attributable to the positive sentiment generated by his election to the presidency.

However, a section of market watchers remain skeptical about the rally and believe that investors have chosen to ignore risks attached to Trump's election. At the same time, recent gains have been more evenly spread across sectors, providing a stronger basis for an extended rally. Economic data has also been largely positive, which means it may be a good idea to add top performers during Trump's first 30 days in office to your portfolios.

Fifth Best Performance Over First 30 Days

The rally which began after Trump's electoral victory has surely been one of the best in recent times. However, the extent of the gains notched up, especially since Trump assumed office have been elaborately illustrated by new data from Dow Jones. During Trump's first 30 days in office, the Dow has gained 4.02% which makes this the fifth best ever in percentage terms.

This also marks the third best performance over such a period for a president serving his first term. Meanwhile, the S&P 500 has gained 3.5% over the same period. This is the best such performance since the increase of 4.6% recorded in 1997, when Bill Clinton won his second term. It is also the fifth best performance ever for the S&P 500 over the first 30 days of a presidential term.

Trump Takes Credit for Market Success

Quite characteristically, President Trump rang in his first month in office by reaffirming his promise to create more jobs in the U.S. At a press conference on Feb 16, Trump talked about recent market gains and said that they were "good for jobs." Earlier in the day, he tweeted a similar message, highlighting the greater sense of optimism in the economy ahead of his proposed tax plan.

On Feb 15, benchmarks hit record highs over a fifth successive session, the longest such stretch of gains for all three major indices since last January. Most market participants attributed such gains to Trump's tax proposals. Even the most critical of experts have admitted that Trump does at least deserve some of the credit. His proposals to deregulate industry have also met with widespread corporate acclaim. On Jan 30, Trump signed an executive order which stipulates that two regulations be eliminated for every new one that is created.

Gains Evenly Spread, Economic Indicators Improve

According to data from S&P Dow Jones Indices, financials within the S&P 500 had gained almost 23% from Nov 8 to the middle of last week. In comparison, stocks from other sectors had gained less than 8% over the same period. In other words, financials increased at a pace at least thrice as fast as stocks from other sectors.

Gains for financials have been largely attributed to Trump's promises about deregulation. The new president has also signed an executive order designed to scale back the Dodd-Frank Act. Trump views the law as a harsh measure, especially for banks.

But since the inauguration, gains have been more evenly spread out across all sectors. Data from S&P Dow Jones Indices shows that financials have gained only 6% over the last 30 days while stocks from other sectors have gained around 3%.

While such a pattern is a clear indication that the rally is likely to continue, the ongoing rally gains further basis from improving economic indicators. Firstly, the new President has inherited a healthy labor market from his predecessor. Additionally, fresh data on retail sales, housing and even inflation has been encouraging. Meanwhile, a private gauge of small business sentiment and the Philadelphia Fed's manufacturing index has each surged to record highs.

Our Choices

Despite its fair share of critics and naysayers, the ongoing rally seems to have gained a second wind. President Trump seems to be largely responsible for stocks' recent gains and many of his upcoming policy actions are likely to boost stocks further.

Picking stocks which have gained from this phenomenon would be a profitable option at this time. We have narrowed down our search to the following stocks based on a good Zacks Rank and other relevant metrics.

Cymabay Therapeutics, Inc. (NASDAQ: CBAY - Free Report ) is a biopharmaceutical company which focuses on the development and commercialization of proprietary new medicines for important human diseases.

Cymabay Therapeutics has a Zacks Rank #1 (Strong Buy). Its expected earnings growth for the current year is 16.3%. Its earnings estimate for the current year has improved by 10.2% over the last 30 days. The stock has returned 87.8% since Jan 20, outperforming the Zacks Medical - Generic Drugs sector, which has gained 12.2% over the same period.

Attunity Ltd. (NASDAQ: ATTU - Free Report ) is a developer, marketer and seller of big data management solutions on a global basis.

Attunity has expected earnings growth of 40.6% for the current year. Its earnings estimate for the current year has improved by 17.4% over the last 30 days. The stock has returned 40.4% since Jan 20, outperforming the Zacks Internet - Software sector, which has gained 2.8% over the same period. The stock has a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Lumentum Holdings Inc. (NASDAQ: LITE - Free Report ) is a manufacturer and seller of innovative optical and photonic products.

Lumentum Holdings has a Zacks Rank #2 (Buy). The company has expected earnings growth of 71% for the current year. Its earnings estimate for the current year has improved by 2.7% over the last 30 days. The stock has returned 45.4% since Jan 20, outperforming the Zacks Lasers Systems and Components sector, which has gained 21.1% over the same period.

Datawatch Corp. (NASDAQ: DWCH - Free Report ) is a provider of Enterprise Reporting, Report Mining and Service Center software products that help organizations increase productivity, reduce costs and gain competitive advantages.

Datawatch has a Zacks Rank #2. The company has expected earnings growth of 70% for the current year. Its earnings estimate for the current year has improved by 20.6% over the last 30 days. The stock has returned 43.9% o since Jan 20, outperforming the Zacks Computer - Software sector, which has gained 4.4% over the same period.

Arconic Inc. (NYSE: ARNC - Free Report ) formed through the separation of aluminum giant Alcoa Inc., is a global leader in multi-material, precision engineered products and solutions for a variety of industries.

Arconic has a Zacks Rank #2. The company has expected earnings growth of 11.9% for the current year. Its earnings estimate for the current year has improved by 18.8% over the last 30 days. The stock has returned 40.5% since Jan 20, outperforming the Zacks Mining - Non Ferrous sector, which has gained 6.8% over the same period.

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?

Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on CBAY - FREE

Get the full Report on ATTU- FREE

Get the full Report on LITE- FREE

Get the full Report on DWCH - FREE

Get the full Report on ARNC - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CymaBay Therapeutics Inc. (CBAY): Free Stock Analysis Report

Attunity Ltd. (ATTU): Free Stock Analysis Report

Lumentum Holdings Inc. (LITE): Free Stock Analysis Report

Datawatch Corporation (DWCH): Free Stock Analysis Report

Arconic Inc. (ARNC): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CBAY ARNC LITE

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More